Key Takeaways

AOD-9604 is purported to support fat loss and body-composition change because it derives from a region of growth hormone associated with lipolytic signaling.
The evidence below supports a much narrower conclusion: animal and mechanistic work suggest plausible metabolic activity, but human therapeutic efficacy has not been established, and public summaries indicate the obesity program ultimately failed to justify continued development.
Current clinic and social-media framing goes well beyond what the evidence supports.
‍

[Heffernan et al., 2001; Valentino et al., 2010; The Guardian, 2025a].

‍

AOD-9604: investigational, unapproved 16-amino-acid human-growth-hormone-derived peptide; a modified analog of the hGH 176–191 region with sequence YLRIVQCRSVEGSCGF, distinguished from the native hGH fragment 176–191 by an N-terminal substitution and from broader hGH biology more generally.

What it is

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic region of human growth hormone. Publicly it has been identified as a modified form of the hGH 176–191 fragment with the sequence YLRIVQCRSVEGSCGF, whereas the native hGH fragment 176–191 is presented separately as FLRIVQCRSVEGSCGF. That distinction matters because the native fragment and the modified investigational analog should not be collapsed into one evidence bucket. [Calzada, 2013; Heffernan et al., 2001]

hGH biology does not equal AOD-9604 outcomes, and AOD-9604 outcomes do not automatically transfer to the unmodified hGH fragment 176–191. The native fragment has been explicitly described as not having been studied in humans, while AOD-9604 has at least some historical human obesity-development literature. [Calzada, 2013; Human Growth Hormone Fragment 176–191 summary]

Material	What it is	Why it cannot be collapsed into "AOD-9604"
Parent human growth hormone	Full endogenous pituitary hormone	Whole-hormone endocrine effects, IGF-1 biology, and approved GH uses are not AOD-9604 evidence.
Native hGH fragment 176–191	Unmodified peptide fragment, sequence distinct at the N-terminus from AOD-9604	Public summaries state it has not been studied in humans; same-molecule human AOD-9604 findings should not be reassigned to it.
AOD-9604	Modified hGH-derived investigational peptide	This is the actual target molecule for the brief. [Calzada, 2013]
Historical oral anti-obesity program	Legacy development context for AOD-9604	Does not validate marketed injectable, compounded, or mixed "wellness" versions. [The Guardian, 2025a]

How it's proposed to work

The best-supported mechanistic backbone comes from preclinical lipolysis work. Public summaries of the foundational animal literature state that AOD-9604 increased lipolysis in obese mice and that beta-3-adrenergic-receptor knockout mice were unresponsive, anchoring the plausible mechanism to sympathetic/lipolytic signaling rather than generalized growth-hormone replacement effects. [Heffernan et al., 2001]

A second, widely repeated mechanistic claim is that AOD-9604 was designed to preserve the fat-metabolism effects of the relevant hGH region without stimulating IGF-1 the way full growth hormone can. Preclinical lipolysis, reduced anabolic spillover, and hGH-fragment ancestry can explain why the molecule sounded plausible as an anti-obesity drug candidate. They do not establish that contemporary AOD-9604 injections reliably reduce body fat, preserve lean mass, or improve outcomes in patients. [Heffernan et al., 2001; Valentino et al., 2010; The Guardian, 2025a]

Common forms in circulation

The historical regulatory/development framing accessible in public summaries describes AOD-9604 as an orally active anti-obesity drug candidate and an investigational peptide with distinct chemical identifiers and a legacy clinical-development arc. [Calzada, 2013]

Current journalism on the Australian peptide market describes AOD-9604 as part of a broader ecosystem of unapproved injectable peptides, often sold through wellness, social-media, or gray-market channels, and often framed around fat loss or body-composition claims. Those routes and formulations should be treated as market behavior, not validated route/dose/formulation evidence. [The Guardian, 2025a; The Guardian, 2025b; news.com.au, 2026]

Names and aliases

Names and near-equivalents include AOD-9604, AOD9604, Anti-Obesity Drug 9604, hGH-derived fragment, hGH 176–191 analog, and human growth hormone fragment derivative. Note the confusion with hGH fragment 176–191, which is not the same molecule. [Calzada, 2013; Human Growth Hormone Fragment 176–191 summary]

Regulatory status

AOD-9604 is unapproved and investigational. No FDA-approved indication or clearly attributable marketed approval under AOD-9604/AOD9604 was identified. That does not mean it is absent from all historical FDA correspondence or all compounding discussions; it does mean current copy should not imply approval. More broadly, FDA's recent peptide enforcement environment has emphasized skepticism toward unapproved peptide categories and active enforcement against online sellers of unapproved drug products. [Reuters, 2024; Reuters, 2026]

In Australia, contemporary reporting describes AOD-9604 as one of the peptides not approved by the TGA and notes broader TGA enforcement against unapproved peptide importation, supply, and advertising. [The Guardian, 2025a; The Guardian, 2025b; news.com.au, 2026]

For athletes, the key practical point is more straightforward. Public reporting of the Essendon/ASADA/WADA episode states that WADA clarified AOD-9604 fell within S0 non-approved substances, and ASADA said its use was prohibited for athletes in any circumstances. [WADA/ASADA reporting, 2013]

Jurisdiction	Current working status	Evidence posture
United States	No approval identified; treat as unapproved/investigational.	Do not imply FDA approval or nationwide settled compounding status. [Reuters, 2024; Reuters, 2026]
European Union	No clearly attributable EMA approval identified	Keep language at "no approval identified," not "definitively unavailable in every member state."
United Kingdom	No clearly attributable MHRA approval identified	Same caution as EU.
Australia	Public reporting describes AOD-9604 as unapproved by the TGA; broader TGA enforcement against unapproved peptide products is active.	Stronger present caution warranted because current reporting is specific to local peptide access. [The Guardian, 2025b; news.com.au, 2026]
Sport/anti-doping	Public reporting states WADA classified AOD-9604 under S0 and ASADA said it is prohibited for athletes.	Do not present as athlete-safe or competition-compatible. [WADA/ASADA reporting, 2013]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Prospective interventional human study of AOD-9604 itself, with route and population stated.	General "clinically proven" language if the effect is small, mixed, or development-ending.
Animal model	In vivo rodent or other animal study using AOD-9604.	Human efficacy, human dosing, or route equivalence.
Mechanistic hypothesis	Pathway, receptor, or tissue-level work; old development rationale.	Patient-facing therapeutic promises.
Anecdotal or commercial	Clinic pages, social-media claims, peptide-market narratives.	Proof of efficacy, safety, regulatory status, or validated dosing.

Purported benefits, by evidence

Purported benefit	Evidence strength	What the evidence supports	What it does not support
Fat loss / lipolysis	Animal model + limited old human trial history	Preclinical work supports lipolytic plausibility; old human-development summaries describe an early obesity-trial signal.	"Clinically proven fat loss peptide," "validated obesity treatment," or predictable current market weight-loss results. [Heffernan et al., 2001; Valentino et al., 2010; Calzada, 2013]
Meaningful weight loss in humans	Weak clinical history	Public summaries indicate older human obesity studies existed.	Strong generalized efficacy; public summaries say later development failed to show enough benefit and the program ended. [Valentino et al., 2010; Calzada, 2013; The Guardian, 2025a]
Works without GH-like side effects	Mechanistic hypothesis / development rationale	Early development framing positioned AOD-9604 as metabolically targeted and distinct from whole hGH.	"Side-effect-free," "safe," or "works like growth hormone without risks." [Calzada, 2013]
Injectable fat-burning therapy	Anecdotal/commercial	Current journalism shows AOD-9604 circulates in injectable peptide markets.	Route equivalence versus legacy oral development, validated dosing, or route-matched safety/efficacy. [The Guardian, 2025a; The Guardian, 2025b]
Better body composition / lean-mass-preserving cut	Mechanistic hypothesis + commercial extrapolation	hGH-fragment ancestry can explain why the claim sounds plausible.	Human proof that contemporary AOD-9604 improves body composition in a clinically meaningful way. [Heffernan et al., 2001; The Guardian, 2025a]
Recovery / performance enhancement	Anecdotal/commercial and anti-doping discourse	It has circulated in athlete-doping controversy and peptide-market discussions.	Any claim of permitted athlete use, performance safety, or sport compatibility. [WADA/ASADA reporting, 2013]

Key literature

Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. Mechanistic plausibility for lipolysis in mouse systems; beta-3-AR knockout mice were unresponsive.

Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013. Confirms at least some human safety/tolerability investigation existed.

Valentino MA, Lin JE, Waldman SA. Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy. Clinical Pharmacology & Therapeutics. 2010. Public summary of the historical obesity program: a 12-week randomized trial reported average loss about 1.8 kg greater than placebo, but a later 24-week trial showed insufficient efficacy and development was terminated.

Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015. Confirms doping detection relevance and ongoing athlete surveillance interest.

References

Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001.
Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013.
Valentino MA, Lin JE, Waldman SA. Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy. Clinical Pharmacology & Therapeutics. 2010.
Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015.
Calzada Limited. AOD9604 – Important Clarifications. April 26, 2013.
Reuters. US FDA warns online vendors selling unapproved weight-loss drugs. Dec 17, 2024.
Reuters. FDA staff question peptides backed by Kennedy ahead of advisory panel review. Jun 30, 2026.
The Guardian. 'Not approved for human use': the online frenzy for injectable peptides sweeping Australia. Dec 6, 2025.
The Guardian. The online wellness clinics letting customers "add to cart" experimental peptides without a doctor consult. Dec 11, 2025.
news.com.au. Therapeutic Goods Administration cracks down on unregulated peptides. Jun 10, 2026.

‍

AOD-9604